Historic Study Showcases Sleep Results of The MDSleep Formulation

Making groundbreaking history in the largest clinical trial on a supplement, MDbio – The Doctors BrandTM MDSleep formulation was shown to benefit sleep sufferers compared to those who were given a placebo, according to a recent press release (1). Data revealed that their formulation helped support a more healthy and restful sleep, as well as, enhance sleep onset. Participants also reported positive progress with their well-being, feelings of anxiety, and stress.

To conduct the clinical trials, Radicle Science, the University of Maryland School of Medicine (Baltimore, Maryland), Harvard T.H. Chan School of Public Health (Boston, Massachusetts), and faculty from the University of California (UCLA) (Los Angeles, California), all worked together and gathered the research. It was one of the largest double-blind randomized placebo-controlled trials in history used to highlight the effectiveness of a non-melatonin supplement to improve sleep (1). To read the full peer-reviewed journal article published in Nutrients, please click here (2).

A diverse mixture of 620 volunteers throughout the US took part in the study and were assigned at random to take one of two formulations of MDSleep, which contained federal legal limits of cannabinoids and additional botanical ingredients or the placebo (1). The first formulation included higher amounts of gamma-aminobutyric acid (GABA), hops oil, valerian oil, and botanical oils, and a lower amount of tetrahydrocannabinol (THC) per serving (.35 mg). For the second formulation, it had larger amounts of THC per serving (.85 mg) and smaller portions of GABA, valerian oil, and hops oil. The botanical oils used were the same portions as the first formulation and included cannabidiol (CBD), cannabinol (CBN), and L-Theanine (1).

According to MDbio’s press release (1) the data revealed:

• A significant improvement in sleep quality (measured by the rate of mean change in the PROMISTM Sleep Disturbance 8a score)
• While not statistically significant, 57.3% of participants experienced a minimal clinically important difference (MCID) in their sleep quality relative to 42.2% of participants in the placebo group. (Note: A score reduction of one-half the standard deviation of the baseline score is considered a MCID).
• A significant improvement in feelings of anxiety (measured by the rate of change in PROMISTM Anxiety 4a score)
• A significant improvement in feelings of stress (measured by the rate of change in the PROMISTM Stress 4a score)
• A significant improvement in well-being (measured by the rate of mean change in the World Health Organization (WHO)-5 Well-being index score)

In regard to the formulation which listed a smaller amount of THC and a higher amount of botanical ingredients (1), the study showed:

• Improve sleep disturbance (sleep quality)
• Aspects that include:
  • Enhance sleep onset
  • Support restful and healthy sleep
  • Improve feeling well-rested upon waking
• Reduce feelings of anxiety and stress
• Promote well-being

With this study’s significant findings, MDbio is conducting clinical trials on other products to see what other data they can discover.

References

1. MDbio. Groundbreaking Study Finds Natural Formulation by MDbio – The Doctors BrandTM Significantly Improves Sleep, Anxiety, Stress, and Overall Well-being https://www.globenewswire.com/news-release/2023/10/03/2753736/0/en/Groundbreaking-Study-Finds-Natural-Formulation-by-MDbio-The-Doctors-BrandTM-Significantly-Improves-Sleep-Anxiety-Stress-and-Overall-Well-being.html#:~:text=Los%20Angeles%2C%20CA%2C%20Oct.,supported%20restful%20and%20healthy%20sleep. (accessed Oct 5, 2023).
2. Kolobaric, A.; Hewlings, S.J.; Bryant, C.; Colwell, C.S.; R. D’Adamo, C.; Rosner, B.; Chen, J.; Pauli, E.K. A Randomized, Double-Blind, Placebo-Controlled Decentralized Trial to Assess Sleep, Health Outcomes, and Overall Well-Being in Healthy Adults Reporting Disturbed Sleep, Taking a Melatonin-Free Supplement. Nutrients 2023, 15, 3788. https://doi.org/10.3390/nu15173788